Is Lymphocyte C-Reactive Protein Ratio Useful for Predicting Survival in Patients with Non-Metastatic Soft Tissue Sarcoma?

Tomoki Nakamura *, Tomohito Hagi, Kunihiro Asanuma ☑ and Akihiro Sudo

Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu 514-8507, Japan
* Correspondence: tomoki66@clin.medic.mie-u.ac.jp; Tel.: +81-592315022; Fax: +81-592315211

Simple Summary: We hypothesized that lymphocyte to C-reactive protein ratio (LCR) could predict survival in 132 patients with soft tissue sarcoma (STS). This study aimed to determine whether LCR before treatment can predict disease-specific survival (DSS) and event-free survival (EFS). The 5-year DSS in patients with higher and lower LCR was 86.5% and 52.8%, respectively (p < 0.001). Patients with lower LCR had worse survival than those with higher LCR. The 5-year EFS in patients with higher and lower LCR was 66.2% and 31.2%, respectively (p < 0.001). On Receiver operating characteristic analysis, however, there was no significant difference in the area under curve (AUC) between CRP level (AUC = 0.72) and LCR (AUC = 0.711). LCR was found to be a poor prognostic factor for oncological outcomes using multivariate analysis, although ROC analysis could not show the superiority of LCR to CRP for predicting oncological outcomes in patients with STS.

Abstract: Background: Recently, the lymphocyte-to-C-reactive protein ratio (LCR) was found to have a prognostic role in many cancers. However, the clinical significance of LCR in patients with soft tissue sarcoma (STS) has not yet been established. This study aimed to determine whether LCR can predict disease-specific survival (DSS) and event-free survival (EFS) in patients with STS. Methods: In this study, 132 patients were enrolled. The mean follow-up periods were 76.5 months. Blood examinations were performed prior to treatment for all patients. Results: The 5-year DSS in patients with higher and lower LCR was 86.5% and 52.8%, respectively (p < 0.001). Patients with lower LCR had worse survival than those with higher LCR. The 5-year EFS in patients with higher and lower LCR was 66.2% and 31.2%, respectively (p < 0.001). On Receiver operating characteristic analysis, however, there was no significant difference in the area under curve (AUC) between CRP level (AUC = 0.72) and LCR (AUC = 0.711). Conclusions: LCR may be a prognostic factor for predicting oncological events in multivariate analysis, although ROC analysis could not show the superiority of LCR to CRP for predicting oncological outcomes in patients with STS.

Keywords: lymphocyte-to-C-reactive protein ratio; soft tissue sarcoma; survival

1. Introduction

Soft tissue sarcoma (STS) is a rare heterogeneous tumor and accounts for 1–2% of all malignancies in adults [1]. Even after radical treatment of primary STS, as many as 50% of these patients experience local recurrence and distant metastasis [2,3]. Therefore, easy, well-known, and low-cost markers may help identifying a high risk for tumor relapse. Inflammation plays a critical role in the development, progression, clinical presentation, and diagnosis of tumors. Elevated C-reactive protein (CRP) has been shown to be a useful predictor for predicting poor survival in patients with STS [4–6]. In all type of peripheral blood cells, Lymphocytes are the most important type, which works against cytotoxic responses to cancer cells. Lymphocytes also work against proliferation of cancer cells, migration of cancer cells, and invasion of cancer cells [7]. Therefore, in the case of lymphocytopenia, the cellular immune system cannot work properly, and inflammatory reaction
cannot be appropriately established. Several studies have shown that absolute lymphocyte counts (ALC) decrease in tumor-induced inflammation and that there is a relationship between the decrease in ALC and poor prognosis [8,9]. Recently, the lymphocyte-to-CRP ratio (LCR) was related to the prognosis in many solid cancers such as hepatocellular carcinoma, colorectal cancer, and esophageal cancer [10–13]. However, the role of LCR in patients with STS has not yet been established. In this study, we aimed to clarify the role of LCR in predicting disease-specific survival (DSS) and event-free survival (EFS) in adult patients with non-metastatic STS. Further aims were to compare the prognostic values of LCR, CRP levels, and lymphocyte count.

2. Materials and Methods

A total of 132 patients with STS who were surgically treated between January 2002 and December 2018 were reviewed. Patients with local recurrence, distant metastasis at initial presentation were excluded from this study. Patients who were referred for additional resection after unplanned excision were also excluded. Finally, Patients with insufficient blood examination data were excluded. The median and mean follow-up periods were 59.5 and 76.5 months, respectively (range: 3.6–207). All patients were examined by chest CT images for finding possible distant metastasis and deciding pretreatment staging. Pathological diagnosis and tumor grades were determined for all patients without myxoid liposarcomas by pathologists using the French Federation of Cancer Centers Sarcoma Group (FNCLCC) grading system. Pathological diagnosis and tumor grades were determined for patients with myxoid liposarcomas using World Health Organization criteria. Blood examinations were performed before any treatment for all patients.

The study was performed in accordance with the ethical standards of the Clinical Research Ethics Review Committee of the Mie University Hospital (H2020-224). Written informed consent was waived, and an “opt-out” option was permitted wherein the patients had an opportunity to deny participation in this study.

Statistical Analysis

The statistical associations were evaluated between clinical backgrounds and LCR using the Mann–Whitney U-test and Kruskal–Wallis test for continuous variables and the chi-squared test for categorical variables. Correlations between LCR, CRP, and ALC were analyzed using Spearman’s rank correlation analysis. The DSS was defined as the time from initial surgery to the date of sarcoma-related death, or the date when the patient was documented to be alive. EFS was defined as the time from surgery were taken from the date of the initial treatment for the primary tumor to the date when the patient was documented to be alive without any oncological events or the date with local recurrence or metastasis. The DSS and EFS were estimated using the Kaplan–Meier method. Cumulative survival was compared using the log-rank test. Univariate and multivariate analyses were performed using the Cox proportional hazards model. The statistical significant variables identified in the univariate analysis included in multivariate analysis A p value < 0.05 was regarded as showing statistical significance. Receiver operating characteristic (ROC) analysis was performed to determine the threshold of LCR, CRP, and ALC at risk of relapse or death within 3 years after surgery. All statistical analyses were performed with the EZR graphical user interface (Saitama Medical Centre, Jichi Medical University, Saitama, Japan) for R (The R Foundation for Statistical Computing, Vienna, Austria). This package is a modified version of R Commander frequently used in biostatistics to add statistical functions.

3. Results

3.1. Patient, Tumor, and Treatment Characteristics

Characteristics of patients are presented in Table 1. The mean and median age of the patients at diagnosis were 63 and 66 years (range: 21–89), respectively. The patients comprised 79 males and 53 females. The mean sizes at diagnosis were 8.9 cm, with a range
of 2 to 30 cm. One hundred and twenty patients had high-grade (grade 2; 38 patients, grade 3; 82 patients), and 12 had low-grade (grade 1) tumors.

Table 1. Patient characteristics.

| Variables | Unit  | Value           |
|-----------|-------|-----------------|
| Age       | mean  | 63 years        |
|           | range | 21–89 years     |
| Sex       | male  | 79              |
|           | female | 53              |
| Size      | mean  | 8.9 cm          |
|           | range | 2–30 cm         |
| depth     | superficial | 25         |
|           | Deep   | 107             |
| Grade     | 1      | 12              |
|           | 2      | 38              |
|           | 3      | 82              |
| CRP       | mg/dL  | 0.155           |
| ALC / µL  |       | 1770            |
| Range     | 0.01–20.4 | 380–3710  |

CRP: C-reactive protein, ALC: absolute lymphocyte count.

Histologically, 29 tumors were undifferentiated pleomorphic sarcomas, 28 were myxofibrosarcomas, 22 were leiomyosarcomas, 13 were de-differentiated liposarcomas, 11 were myxoid liposarcomas, 8 were malignant peripheral nerve sheath tumors, 6 were synovial sarcomas, 5 were fibrosarcomas, and 10 were other STSs.

The STS arose 55 at the thigh, 17 at the leg, 11 at the buttock, 10 at the upper arm, 9 at the chest wall, 8 at the back, and 22 at other sites. We included 3 retroperitoneal STSs. The tumor depth was as follows: superficial in 25 patients and deep-seated in 107 patients. Ten patients underwent adjuvant radiotherapy, and 31 patients underwent perioperative chemotherapy.

3.2. The Relationship between the LCR and Clinical Characteristics

The median CRP level was 0.155 mg/dL (range: 0.01–20.4). The median ALC was 1770/µL (range: 380–3710). The median LCR was 13,518 (range: 19.9–273,000). On ROC analysis, a value of 9608.696 was an appropriate threshold for LCR to identify if patients were at risk of death within 3 years (area under the curve [AUC] = 0.711; 95% confidence interval [CI]: 0.62–0.802). The relationship between the clinicopathological features and LCR is shown in Table 2. Tumor grade and size were significantly associated with LCR.

Table 2. Relationship between lymphocyte-to-C-reactive protein ratio and clinical characteristics.

| Variables | Unit     | Low LCR | High LCR | p Value |
|-----------|----------|---------|----------|---------|
| Age       | mean     | 63      | 63       | 0.843   |
|           | age      | 39      | 40       | 0.107   |
|           | female   | 18      | 35       |         |
| Size      | mean     | 5.7     | 4.9      | 0.011   |
|           | superficial | 7     | 18       | 0.117   |
|           | deep     | 50      | 57       |         |
| Grade     | 1        | 1       | 11       | <0.001  |
|           | 2        | 11      | 27       |         |
|           | 3        | 45      | 37       |         |

LCR: lymphocyte-to-C-reactive protein ratio.

3.3. Overall DSS and Predictors of Mortality

At the final follow-up, 99 patients (94/132; 71.2%) were alive, 38 had died of disease, and 8 had died of other disease. The 5-year DSS was 71.8% (95% CI: 62.8–79.1) in all
132 patients. Next, we divided the patients into two groups according to the value of LCR using ROC analysis. Patients with lower LCR had worse survival than those with higher LCR. The 5-year DSS in patients with higher (n = 75) and lower (n = 57) LCR was 86.5% (95% CI: 75.6–92.8) and 52.8% (95% CI: 38.3–65.4), respectively (p < 0.001, log-rank test) (Figure 1).

A Cox proportional univariate analysis confirmed that tumor size (p < 0.001), CRP level (p < 0.001), and LCR (p < 0.001) (Table 3) were significant prognostic factors. Tumor size and CRP level were also prognostic factors in multivariate analysis.

Table 2. Relationship between lymphocyte-to-C-reactive protein ratio and clinical characteristics.

| Variables         | Unit | Univariate Analysis | Multivariate Analysis |
|-------------------|------|---------------------|-----------------------|
|                   |      | HR                  | 95% CI                | p Value | HR                  | 95% CI                | p Value |
| Age               | years| 1.019               | 0.994–1.044           | 0.139   | 1.096               | 1.039–1.157           | <0.001  |
| Sex               |      | female              | 1                     |         | male                | 0.8772               | 0.461–1.671           | 0.69    |
| Size              | cm   | 1.116               | 1.063–1.171           | <0.001  | 1.096               | 1.039–1.157           | <0.001  |
| Depth             |      | s.c                 | 0.739                 | 0.308–1.771 | 0.498 |
| Grade             |      | 1                   | 3.18                  | 0.403–25.1 | 0.273 |
|                   |      | 2                   | 5.372                 | 0.731–39.53 | 0.099 |
| Histology         |      | MFS                 | 2.034                 | 0.680–6.080 | 0.204 |
|                   |      | UPS                 | 1.874                 | 0.715–4.915 | 0.202 |
|                   |      | Others              | 2.548                 | 0.797–7.323 | 0.190 |
| Cx                |      | No                  | 1.58                  | 0.797–3.133 | 0.190 |
| LCR               |      | high                | 3.206                 | 1.638–6.277 | <0.001 |
|                   |      | Low                 | 1.177                 | 1.099–1.25   | <0.001   |
| CRP               | mg/dL|                     | 0.999                 | 0.999–1      | 0.35     |
| ALC               | µL   |                     |                       |          |

LCR: lymphocyte-to-C-reactive protein ratio, CRP: C-reactive protein, ALC: absolute lymphocyte count, s.c: superficial, HR: hazard ratio, 95% CI: 95% confidential interval, MFS: myxofibrosarcoma, UPS: Undifferentiated pleomorphic sarcoma, Cx: perioperative chemotherapy.
3.4. Event-Free Rate and Predictors of Events

Of the 132 patients, 33 (25%) and 57 (43.1%) showed local tumor recurrence and distant metastasis, respectively. The 5-year event-free rate was 51% (95% CI: 41.9–59.3). Patients with lower LCR had worse survival than those with higher LCR. The 5-year EFS in patients with higher (n = 75) and lower (n = 57) LCR was 66.2% (95% CI: 53.7–76.1) and 31.2% (95% CI: 19.7–43.5), respectively (p < 0.001, log-rank test) (Figure 2). Cox proportional univariate analysis revealed that CRP level (p < 0.001), LCR (p < 0.001), tumor size (p < 0.001), age (p = 0.037), tumor depth (p = 0.038), and histological tumors (grade 3; p = 0.012) were significant predictors of the occurrence of events in STS patients. Multivariate analysis showed that CRP level (p < 0.001) and tumor size (p < 0.001) remained independent predictors of oncological events (Table 4).

Figure 2. Kaplan–Meier curves showing event-free survival. A: Patients with a higher lymphocyte-to-C-reactive protein ratio; B: Patients with a lower lymphocyte-to-C-reactive protein ratio.

Table 4. Univariate and multivariate event-free survival analyses.

| Variables | Unit      | Univariate Analysis | Multivariate Analysis |
|-----------|-----------|---------------------|-----------------------|
|           |           | HR                  | 95% CI                | p Value | HR                  | 95% CI                | p Value |
| Age       | years     | 1.018               | 1.001–1.036           | 0.037   | 1.017               | 0.999–1.036           | 0.063   |
| Sex       |           | female 1            | 1                     | 0.942   | 0.586–1.513         | 0.804                 |     |
|           |           | male 1              | 0.81                  | 0.379–1.73 | 0.586                  | 0.397–1.73            |     |
| Size      | cm        | 1.108               | 1.064–1.154           | <0.001  | 1.079               | 1.028–1.133           | <0.001  |
|           |           | depth deep 1        | 0.81                  | 0.379–1.73 | 0.586                  | 0.397–1.73            |     |
| Grade     |           | 2                   | 3.589                 | 0.828–15.55 | 0.088                  | 2.156                 | 0.483–9.627          | 0.315   |
| Histology |           | MFS 1               | 1                     |        |                      |                       |         |
|           |           | UPS 1               | 1.442                 | 0.673–3.087 | 0.347                  |                       |         |
|           |           | Others 1            | 1.711                 | 0.902–3.246 | 0.1                    |                       |         |
| Cx        |           | No 1                | 1.635                 | 0.987–2.709 | 0.0561                 |                       |         |
|           |           | Yes 1               | 1                     |        |                      |                       |         |
| LCR       |           | High 1              | 2.438                 | 1.522–3.905 | <0.001                | 1.462                 | 0.849–2.52          | 0.171   |
|           |           | Low 1               | 1                     |        |                      |                       |         |
| CRP       | mg/dL     | 1.187               | 1.123–1.255           | <0.001  | 1.123               | 1.051–1.2            | <0.001  |
| ALC       | /µL       | 0.999               | 0.999–1              | 0.676   |                      |                       |         |

LCR: lymphocyte-to-C-reactive protein ratio, CRP: C-reactive protein, ALC: absolute lymphocyte count, s.c: superficial, HR: hazard ratio, 95% CI: 95% confidential interval, MFS: myxofibrosarcoma, UPS: Undifferentiated pleomorphic sarcoma, Cx: perioperative chemotherapy.
3.5. ROC Analysis

On ROC analysis, LCR was found to be a significantly appropriate marker (AUC = 0.711) for identifying whether patients were at risk of further diseases or death within 3 years compared with ALC (AUC = 0.471, \( p = 0.001 \)) (Figure 3). However, there was no significant difference in the AUC between CRP level (AUC = 0.72) and LCR (\( p = 0.282 \)) (Figure 4).

![ROC Curve](image)

**Figure 3.** Receiver operating characteristic curve showing significant difference in area under the curve between absolute lymphocyte count (solid line) and lymphocyte-to-C-reactive protein ratio (dotted line).

![ROC Curve](image)

**Figure 4.** Receiver operating characteristic curve showing no significant difference in area under the curve between C-reactive protein level (solid line) and lymphocyte-to-C-reactive protein ratio (dotted line).

4. Discussion

In the present study, we showed that LCR was associated with DSS and EFS in 132 patients with STS in univariate and multivariate analysis. However, on ROC analysis,
the AUC of CRP for predicting survival was similar to that of LCR. We believe that the present results were affected by ALC.

We could not determine whether ALC was related to clinical outcomes, and ROC analysis showed that ALC was a poor indicator for predicting survival and oncological events. ALC has been associated with mortality in several cancers, including gastric, cervical, renal cell and lung cancers [7,8,14–18]. Brewster et al. reported that ALC at diagnosis were significantly inversely associated with overall survival in 634 patients with musculoskeletal sarcomas [19]. The median ALC was 1120/µL as per their study. They classified patients were classified as having lymphopenia if they had an ALC value less than 1000/µL. However, in the present study, we included only four patients with ALC values less than 1000/µL. Furthermore, the median ALC was 1770/µL. Teck et al. reported that the neutrophil-to-lymphocyte and lymphocyte-monocyte ratios were related to survival in 142 sarcoma patients, although they could not determine whether ALC was related to survival [20]. The median ALC was 1810/µL in their study. Therefore, we believe that the distribution of ALC may differ between cohorts; thus, the relationship between ALC and survival may be different. Nevertheless, the association of lymphocytes with host immunity and tumor progression should be considered. Lymphocyte plays prominent role in the tumor related immunity, which contribute to host defense [21–24]. Therefore, lymphocyte related prognostic tools, such as neutrophil to lymphocyte ratio and platelet to lymphocyte ratio, were reported in patients with STS [25–28].

In the present study, CRP was an independent prognostic marker for predicting survival and oncological events in multivariate analysis. CRP has been widely reported to be an independent prognostic marker in patients with STS [4–6,29,30]. The cohort with elevated CRP may be suitable for future clinical trials of intensive therapy.

This study had certain limitations. The retrospective nature of the study is a limitation. Although all patients had undergone chest CT scans and routine blood examinations to rule out the presence of metastasis and/or other cancers, other chronic disease that may increase CRP levels were not taken into consideration due to the lack of information. Furthermore, the distribution of ALC may differ between cohorts, even if the measurement was obtained before treatment in all patients. We also should consider the possible affection of small number of the patients with adjuvant radiotherapy and chemotherapy for oncological outcome in the present study, although adjuvant radiotherapy is not often performed if the adequate surgical margin is acquired in Japan. Further multicenter studies including other countries should be necessary to validate the present findings.

5. Conclusions

LCR was found to be a poor prognostic factor for oncological outcomes in patients with STS using multivariate analysis, although ROC analysis could not show the superiority of LCR to CRP for predicting oncological outcomes in patients with STS.

Author Contributions: Conceptualization, T.N.; methodology, T.N.; software, T.N.; validation, T.N. and K.A.; formal analysis, T.N. and T.H.; investigation, T.N., K.A. and T.H.; resources, T.N., K.A. and T.H.; data curation, T.N; writing—original draft preparation, T.N.; writing—review and editing, K.A. and A.S.; visualization, T.N.; project administration, T.N.; funding acquisition; A.S.; supervision, A.S. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: This study was approved by the Clinical Research Ethics Review Committee of Mie University Hospital (H2020-224).

Informed Consent Statement: The need for patient consent was waived due to the retrospective nature of the study.

Data Availability Statement: No new data were created or analyzed in this study. Data sharing is not applicable to this article.

Conflicts of Interest: The authors declare no conflict of interest.
References

1. Clark, M.A.; Fisher, C.; Judson, I.; Thomas, J.M. Soft-Tissue Sarcomas in Adults. *N. Engl. J. Med.* 2005, 353, 701–711. [CrossRef] [PubMed]

2. Gunar, K.Z.; Matthew, T.B.; Peter, W.T.; Raphael, E.P.; Shreyaskumar, R.P.; Robert, S.B.; Harry, L.E. Prognostic factors for patients with localized soft-tissue sarcoma treated with surgery and radiation therapy. *Cancer* 2003, 97, 2530–2543. [CrossRef]

3. Nakamura, T.; Asanuma, K.; Takao, M.; Yamanaka, T.; Koike, H.; Chen-Yoshikawa, T.F.; Tsukushi, S.; Kuroda, H.; Kozawa, E.; Sano, M.; et al. Clinical Outcome in Soft Tissue Sarcoma Patients with Lung Metastasis Who Received Metastasectomy and/or Radiofrequency Ablation: Tokai Musculoskeletal Oncology Consortium Study. *Cancer Manag. Res.* 2021, 13, 8473–8480. [CrossRef]

4. Wang, X.; Liu, S.; Zhao, X.; Fang, E.; Zhao, X. The value of C-reactive protein as an independent prognostic indicator for disease-specific survival in patients with soft tissue sarcoma: A meta-analysis. *PLoS ONE* 2019, 14, e0219215. [CrossRef] [PubMed]

5. Nakamura, T.; Matsumine, A.; Matsubara, T.; Asanuma, K.; Uchida, A.; Sudo, A. Clinical significance of pretreatment serum C-reactive protein level in soft tissue sarcoma. *Cancer* 2011, 118, 1055–1061. [CrossRef] [PubMed]

6. Nakamura, T.; Grimer, R.; Gaston, C.; Francis, M.; Charman, J.; Graunt, P.; Uchida, A.; Sudo, A.; Jeyes, L. The value of C-reactive protein and comorbidity in predicting survival of patients with high grade soft tissue sarcoma. *Eur. J. Cancer* 2013, 49, 377–385. [CrossRef] [PubMed]

7. Wu, E.S.; Oduyebo, T.; Cobb, L.P.; Cholakian, D.; Kong, X.; Fader, A.N.; Levinson, K.L.; Tanner, E.J.; Stone, R.L.; Piotrowski, A.; et al. Lymphopenia and its association with survival in patients with locally advanced cervical cancer. *Gynecol. Oncol.* 2015, 140, 76–82. [CrossRef]

8. Clark, E.; Connor, S.; Taylor, M.; Madhavan, K.; Garden, O.; Parks, R. Preoperative lymphocyte count as a prognostic factor in resected pancreatic ductal adenocarcinoma. *HPB* 2007, 9, 456–460. [CrossRef]

9. Feng, J.-F.; Liu, J.-S.; Huang, Y. Lymphopenia Predicts Poor Prognosis in Patients With Esophageal Squamous Cell Carcinoma. *Medicine* 2014, 93, e257. [CrossRef]

10. Okugawa, Y.; Toiyama, Y.; Yamamoto, A.; Shigemori, T.; Ide, S.; Kitajima, T.; Fujikawa, H.; Yasuda, H.; Hiro, J.; Yoshiyama, S.; et al. Lymphocyte-C-reactive Protein Ratio as Promising New Marker for Predicting Surgical and Oncological Outcomes in Colorectal Cancer. *Ann. Surg.* 2019, 272, 342–351. [CrossRef]

11. Angin, Y.S.; Yildirim, M.; Dasiran, F.; Okan, I. Could lymphocyte to C-reactive protein ratio predict the prognosis in patients with gastric cancer? *ANZ J. Surg.* 2021, 91, 1521–1527. [CrossRef]

12. Iseda, N.; Itoh, S.; Yoshizumi, T.; Tomiyama, T.; Morinaga, A.; Shimagaki, T.; Wang, H.; Kurihara, T.; Toshima, T.; Nagao, Y.; et al. Lymphocyte-to-C-reactive protein ratio as a prognostic factor for hepatocellular carcinoma. *Int. J. Clin. Oncol.* 2021, 26, 1890–1900. [CrossRef] [PubMed]

13. Takeuchi, M.; Kawakubo, H.; Hoshino, S.; Matsuda, S.; Mayanagi, S.; Irimo, T.; Fukuda, K.; Nakamura, R.; Wada, N.; Kitagawa, Y. Lymphocyte-to-C-Reactive Protein Ratio as a Novel Marker for Predicting Oncological Outcomes in Patients with Esophageal Cancer. *World J. Surg.* 2021, 45, 3370–3377. [CrossRef] [PubMed]

14. Park, S.J.; Lee, J.; Kim, H.; Shin, K.; Lee, M.; Park, J.M.; Choi, M.-G.; Park, C.H.; Song, K.Y.; Lee, H.H.; et al. Association between absolute lymphocyte count and overall mortality in patients with surgically resected gastric cancer. *Korean J. Intern. Med.* 2021, 36, 679–686. [CrossRef] [PubMed]

15. Karantanos, T.; Karanika, S.; Seth, B.; Gignac, G. The absolute lymphocyte count can predict the overall survival of patients with non-small cell lung cancer on nivolumab: A clinical study. *Clin. Transl. Oncol.* 2018, 21, 206–212. [CrossRef] [PubMed]

16. Ueda, K.; Suekane, S.; Kurose, H.; Ogasawara, N.; Hiroshige, T.; Chikui, K.; Uemura, K.; Nakiri, M.; Nishihara, K.; Matsuo, M.; et al. Absolute lymphocyte count is an independent predictor of survival in patients with metastatic renal cell carcinoma treated with nivolumab. *Jpn. J. Clin. Oncol.* 2021, 52, 179–186. [CrossRef]

17. Suriu, C.; Akria, L.; Azoulay, D.; Shauol, E.; Barhoum, M.; Braester, A. Absolute lymphocyte count as a prognostic marker in newly diagnosed multiple myeloma patients. *Int. J. Lab. Hematol.* 2016, 38, e56–e59. [CrossRef] [PubMed]

18. Johnson, M.E.; Zhu, F.; Li, T.; Wu, H.; Galloway, T.J.; Farma, J.M.; Perlis, C.S.; Turaka, A. Absolute lymphocyte count: A potential prognostic factor for Merkel cell carcinoma. *J. Am. Acad. Dermatol.* 2014, 70, 1028–1035. [CrossRef]

19. Brewer, R.; Purington, N.; Henry, S.; Wood, D.; Ganjoo, K.; Uemura, K.; Nishihara, K.; Matsuo, M.; et al. Absolute lymphocyte count in patients with metastatic renal cell carcinoma with or without nivolumab. *Blood* 2018, 132, 2721–2730. [CrossRef] [PubMed]

20. Seo, S.T.; Singh, V.A.; Yasin, N.F. Preoperative lymphocyte count in relation to sarcoma prognosis. *J. Orthop. Surg.* 2019, 27, 2394949019854957. [CrossRef]

21. Wang, Y.; Zhou, N.; Liu, H.; Gong, X.; Zhu, R.; Li, X.; Sun, Z.; Zong, X.; Li, N.; Meng, C.; et al. Circulating activated lymphocyte subsets as potential blood biomarkers of cancer progression. *Cancer* 2020, 9, 5086–5094. [CrossRef] [PubMed]

22. Mellman, I.; Coukos, G.; Dranoff, G. Cancer immunotherapy comes of age. *Nature* 2011, 480, 480–489. [CrossRef] [PubMed]

23. Liu, P.; Chen, L.; Zhang, H. Natural Killer Cells in Liver Disease and Hepatocellular Carcinoma and the NK Cell-Based Immunotherapy. *J. Immunol. Res.* 2018, 2018, 1206737. [CrossRef] [PubMed]

24. Zanetti, M. Tapping CD4 T Cells for Cancer: Natural Killer Cells: The Choice of Personalized Genomics. *J. Immunol.* 2015, 194, 2049–2056. [CrossRef]
25. Nakamura, T.; Matsumine, A.; Matsubara, T.; Asanuma, K.; Uchida, A.; Sudo, A. The combined use of the neutrophil-lymphocyte ratio and C-reactive protein level as prognostic predictors in adult patients with soft tissue sarcoma. *J. Surg. Oncol.* 2013, 108, 481–485. [CrossRef] [PubMed]

26. García-Ortega, D.Y.; Álvarez-Cano, A.; Sánchez-Llamas, L.A.; Caro-Sánchez, C.H.; Martínez-Said, H.; Luna-Ortiz, K.; Cuéllar-Hübbe, M. Neutrophil/lymphocyte ratio is associated with survival in synovial sarcoma. *Surg. Oncol.* 2018, 27, 551–555. [CrossRef] [PubMed]

27. Que, Y.; Qiu, H.; Li, Y.; Chen, Y.; Xiao, W.; Zhou, Z.; Zhang, X. Preoperative platelet-lymphocyte ratio is superior to neutrophil-lymphocyte ratio as a prognostic factor for soft-tissue sarcoma. *BMC Cancer* 2015, 15, 648. [CrossRef]

28. Szkandera, J.; Gerger, A.; Liegl-Atzwanger, B.; Absenger, G.; Stotz, M.; Friesenbichler, J.; Trajanoski, S.; Stojakovic, T.; Eberhard, K.; Leithner, A.; et al. The lymphocyte/monocyte ratio predicts poor clinical outcome and improves the predictive accuracy in patients with soft tissue sarcomas. *Int. J. Cancer* 2013, 135, 362–370. [CrossRef]

29. Nakamura, T.; Katagiri, H.; Shido, Y.; Hamada, S.; Yamada, K.; Nagano, A.; Yamada, S.; Tsukushi, S.; Ishimura, D.; Matsumine, A.; et al. Analysis of Factors for Predicting Survival in Soft-tissue Sarcoma with Metastatic Disease at Initial Presentation. *Anticancer Res.* 2017, 37, 3137–3141. [CrossRef]

30. Fujibuchi, T.; Miyawaki, J.; Kidani, T.; Imai, H.; Miura, H. Prediction of Soft Tissue Sarcoma from Clinical Characteristics and Laboratory Data. *Cancers* 2020, 12, 679. [CrossRef]